Strong Programs Start With Better Questions

Sarah Sink
10 hours ago
3 min read

Most development programs begin with the same priorities. Move quickly, generate strong data, and reach the next milestone with confidence.

But many teams discover the same realization months into execution.

The most important questions were never asked at the beginning.

Early conversations between biotech companies and CDMOs usually focus on capabilities, timelines, and cost. Those topics matter, but they are rarely the questions that determine whether execution will feel smooth or frustrating later.

The programs that move forward with confidence tend to be the ones where the right questions were asked early.

Too often, those questions only surface once the work is already underway.

Why Early Questions Matter

At the start of a partnership, everything appears possible.

Processes look scalable.

Analytical methods appear ready.

Manufacturing timelines feel achievable.

Sterile fill finish seems like a straightforward final step.

But development programs evolve quickly. As more data becomes available and operational realities emerge, assumptions begin to shift.

The right early questions help teams understand not only what a partner can do, but how they approach complexity when it inevitably appears.

That difference often determines whether programs move smoothly or encounter unexpected delays.

The Questions That Reveal Execution Readiness

Some of the most valuable questions are not highly technical. They focus on how work will actually happen.

For example:

How are risks surfaced and communicated during the program?

How early are SMEs involved in development and manufacturing decisions?

What happens when timelines need to adjust?

How does the team evaluate readiness for tech transfer?

These conversations reveal how partners think about execution.

A strong partner will not simply provide reassuring answers. They will explain how challenges are identified and addressed before they become problems.

Those insights often tell you far more about future success than a long list of capabilities.

Why Sterile Fill Finish Should Be Discussed Early

Sterile fill finish is often viewed as a downstream step that will be addressed once drug product manufacturing is established.

In reality, decisions made earlier in development can strongly influence fill-finish success.

Container closure systems, formulation stability, filtration strategy, and line compatibility all benefit from early discussion. When fill-finish teams are included sooner, they can identify constraints and opportunities that might otherwise appear later in the program.

Programs that integrate sterile fill finish thinking early reduce the risk of late-stage adjustments that disrupt timelines.

Many teams only ask these questions once they reach fill-finish planning.

By then, options may already be limited.

The Role of CDMO Collaboration

No development program succeeds in isolation. Collaboration between biotech teams and CDMOs determines how well plans translate into execution.

The strongest partnerships encourage open discussion from the beginning. Teams ask thoughtful questions, share realistic expectations, and explore potential challenges before they become operational issues.

From a business development perspective, this is where partnership quality becomes clear.

Strong partners welcome detailed questions because they understand that clarity early creates smoother execution later.

Business Development as a Strategic Connector

Business development professionals often help guide these early conversations.

They connect sponsor goals with operational insight. They understand which questions uncover risk, which discussions prevent friction, and how early alignment shapes downstream execution.

Strong BD professionals know that the best partnerships are built on transparency and thoughtful dialogue.

The goal is not simply to answer questions. It is to ensure both teams understand how the work will actually unfold.

What Strong Programs Do Differently

Programs that maintain momentum tend to share several habits:

They ask detailed questions early
They involve SMEs before key decisions are made
They connect development choices to manufacturing and fill-finish realities
They revisit assumptions as programs evolve
They treat communication as part of execution, not an afterthought

These behaviors help programs move forward with fewer surprises.

Final Thoughts

In development programs, delays often trace back to questions that were never asked early enough.

Strong partnerships begin with curiosity, transparency, and a willingness to explore potential challenges before they appear.

If your team is evaluating CDMOs or comparing proposals, the questions you ask early may be the difference between smooth execution and months of avoidable delay. My guide, How to Compare CDMO Quotes: 10 Factors Beyond Cost, helps biotech teams evaluate potential partners beyond surface-level proposals so they can identify the teams best equipped to support development, manufacturing, and sterile fill finish.

Because the questions most teams ask too late are often the ones that matter most.

For more insights and personalized support in navigating the biotech-CDMO landscape, visit www.yourpharmagirl.com and follow Your Pharma Girl on LinkedIn. Whether you need strategic guidance, tailored business development solutions, or expert advice on building lasting partnerships, I am here to help you and your team succeed at every stage of development.